Skip to main content
Xspray Pharma logo

Xspray Pharma — Investor Relations & Filings

Ticker · XSPRAY ISIN · SE0023312764 LEI · 549300NGRQCNZ3X4L157 ST Manufacturing
Open in API
Filings indexed 254 across all filing types
Latest filing 2020-08-18 Regulatory Filings
Country SE Sweden
Listing ST XSPRAY

About Xspray Pharma

https://xspraypharma.com/

Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.

Recent filings

Filing Released Lang Actions
Xspray stärker värdet på produktportföljen med patent för dasatinib propylenglykolsolvat tablett
Regulatory Filings Classification · 95% confidence The document is a press release from Xspray Pharma AB announcing that it has received a "Notice of Allowance" from the USPTO for a patent related to a dasatinib tablet formulation. This announcement concerns intellectual property rights, patent strategy, and its impact on the product portfolio and commercialization strategy. This type of announcement, which details specific legal/IP developments rather than general financial results (ER/IR) or management changes (MANG), fits best under the general category of Regulatory Filings (RNS) or potentially Legal Proceedings Report (LTR) if it were about a lawsuit. However, since it is a positive announcement regarding a patent grant/allowance, which is a key regulatory/legal milestone, and it is not a standard financial report, the most appropriate general regulatory/miscellaneous category is RNS, as it is a formal regulatory update that doesn't fit the other specific codes like DIV, CAP, or DIRS. The document also explicitly states it is information Xspray Pharma AB is obligated to disclose under EU market abuse regulation, confirming its nature as a regulatory disclosure.
2020-08-18 Swedish
Xspray meddelar preliminära resultat från den första studien för sin ledande produktkandidat HyNap-Dasa
Regulatory Filings Classification · 95% confidence The document is a press release from Xspray Pharma AB announcing preliminary results from a clinical study (bioequivalence study) for a product candidate (HyNap-Dasa). It details the outcome, next steps (discussion with FDA, upcoming second study results), and includes a call for an investor conference. This type of announcement, focusing on preliminary clinical trial data and immediate operational updates, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement of preliminary financial/operational results (even if clinical in nature) and not a comprehensive report (like 10-K or IR), ER is a strong candidate. However, given the context of a specific, non-quarterly operational update that is regulatory in nature (required to be made public under EU MAR), and the presence of an attached PDF link, it fits well into the general 'Regulatory Filings' (RNS) category if ER is reserved strictly for quarterly financial summaries. Since it announces key operational results and includes a link to the full document, it functions as a regulatory disclosure. Given the options, and that it is a specific, time-sensitive announcement of operational progress rather than a comprehensive financial report, RNS (Regulatory Filings) is the most appropriate general category for this type of market-sensitive disclosure that isn't explicitly covered by other codes like ER (which usually implies quarterly earnings). The document length is moderate (5629 chars), and it is the primary disclosure itself, not just an announcement of a report, thus avoiding the RPA classification.
2020-08-12 Swedish
Xspray announces preliminary results from the first study for its lead product candidate HyNap-Dasa
Regulatory Filings Classification · 99% confidence The document is a press release announcing preliminary clinical study results for a product candidate (HyNap-Dasa). It discusses bioequivalence studies, interactions with the FDA regarding an ANDA application, and schedules an audiocast. This type of announcement, which details specific operational or clinical progress without being a full financial report (like 10-K or IR) or a formal regulatory filing notification, fits best under the general 'Regulatory Filings' (RNS) category, as it is a mandatory disclosure under EU Market Abuse Regulation, but doesn't fit the more specific categories like ER (Earnings Release) or LTR (Legal Proceedings). Given the context of clinical trial updates and regulatory pathway discussions, RNS is the most appropriate general disclosure category.
2020-08-12 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Xspray Pharma Delårsrapport Q2 2020' (Interim Report Q2 2020) and covers the period 'Januari - juni 2020'. It contains detailed financial statements, including income statements, cash flow data, and key performance indicators for the group and parent company. It also includes a 'VD har ordet' (CEO statement) and business updates. Since it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. H1 2020
2020-07-31 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Xspray Pharma Interim report Q2 2020' and covers the period 'JANUARY - JUNE 2020'. It contains detailed financial tables, including income statements and cash flow data for the group and parent company, as well as a CEO message and business analysis. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2020
2020-07-31 English
Xspray Pharma initiates pivotal registration studies with HyNap-Dasa for the market approval application in the United States
Regulatory Filings Classification · 95% confidence The document announces a specific corporate event: the initiation of pivotal clinical bioequivalence studies for a product candidate (HyNap-Dasa) to support a future market approval application in the US. It contains company updates, contact information, and concludes with a statement that the information is made public pursuant to the EU Market Abuse Regulation, followed by an attachment link. This structure strongly suggests a general regulatory announcement or press release regarding operational progress, rather than a formal financial report (like 10-K or IR) or a specific shareholder action document (like DEF 14A or DVA). Since it is a general regulatory announcement that doesn't fit the highly specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate fallback category is Regulatory Filings (RNS). The document length (3871 chars) is short enough that it might be considered an announcement of information rather than the full report, but RNS covers the nature of the disclosure itself.
2020-05-29 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.